Medicines for Malaria Venture (MMV)

19/06/2026

We cannot meet today’s health needs—let alone tomorrow’s—with yesterday’s tools.

As funding gaps widen and calls for more country-led health systems grow louder, discussions about global health reform are becoming increasingly urgent. But reform is not only about improving coordination and delivery; it must also preserve the ability to develop the next generation of health tools.

In a new Project Syndicate op-ed, leaders from MMV, DNDi and GARDP argue that product development partnerships (PDPs) have an important role to play in ensuring remains central to a more resilient, country-led global health system.

This vision is at the heart of the recent strategic cooperation agreement between MMV, DNDi and GARDP, which brings together complementary expertise to strengthen innovation and maximize the impact of limited global health R&D resources.

Because the health challenges of tomorrow will require a new generation of tools, and a global health system that supports their development and delivery.

Read more: bit.ly/4oyhtzo

17/06/2026

Global health is being asked to do more with less. At the same time, the possibilities for have never been greater.

That is why MMV and Drugs for Neglected Diseases initiative (DNDi) are pooling regulatory expertise within a new Joint Regulatory Platform, led by Fabienne Benoist.

Developing and delivering medicines for some of the world’s most underserved diseases requires novel approaches. Bringing these innovations to patients faster also requires earlier collaboration with regulatory authorities, more adaptive approaches to evidence, and in some cases, the development of entirely new standards.

This joint platform is designed to help meet that need. By bringing together the regulatory expertise of both organizations, we will:

→ Pool our knowledge and speak with one voice
→ Help define the evidence standards that future medicines will require
→ Strengthen our impact

We believe this is a model the wider global health community can build on—because ultimately, success is measured by one thing: getting better medicines to patients faster.

Read more: bit.ly/4a4OEEP

16/06/2026

Open-access tools can help researchers make better decisions earlier in the drug discovery process.

That's why MMV continues to invest in , our free open-access dose-to-human prediction platform.

The latest version introduces several new features to support human dose prediction from early discovery onwards:

🔹 Dose prediction tools for long-acting injectables (LAIs), a first in an open-access drug discovery tool
🔹 Enhanced, interactive plots and tables for clearer comparison of dose predictions
🔹 Improved models to better estimate drug properties like free fraction
🔹 Built-in documentation and user guides to make the tool easier to use

And there's more to come, with new LAI optimization tools and expanded functionality on the way.

Try it here: https://www.mmvsola.org/

Feedback is welcome. Help us shape future versions!

15/06/2026

The antimalarial toolbox we have today was built through partnership. The next generation of interventions will be too.

From drug resistance to changing transmission patterns, the challenges facing control and elimination are becoming more complex. Meeting them will require new tools, sustained investment in innovation and strong partnerships.
Product development partnerships (PDPs) like MMV bring together the expertise needed to turn scientific discovery into tools that reach patients: from researchers and clinical trial networks to manufacturers, regulators and funders.

In a recent interview with Healthcare Outlook, MMV CEO Martin Fitchet reflects on why the PDP model remains essential to advancing innovation and responding to emerging threats such as drug resistance.

Read how MMV and partners are working to fill the antimalarial pipeline with the next generation of interventions:

Medicines for Malaria Venture is continuing to innovate its R&D pipeline, collaborate with stakeholders, and refine its product development partnership model. Dr Martin Fitchet, CEO, tells us more.

11/06/2026

To accelerate elimination, the next generation of antimalarials must be developed with simplicity in mind.

Malaria chemoprevention is already a proven strategy for protecting at-risk populations, particularly children and pregnant women. However, many current approaches require repeated dosing over extended periods. Tools that provide longer protection with fewer administrations could help make prevention easier to deliver and more resilient in real-world settings.

Long-acting injectables (LAIs) can help achieve this. By providing lasting protection from a single intervention, LAIs have the potential to simplify prevention and extend protection over longer periods.

MMV and the Gates Foundation recently convened partners and experts from across sectors to explore the opportunities and challenges surrounding the discovery, development, implementation and equitable access of LAIs for high-burden diseases.

The discussions focused on how this can be developed to respond to the realities of communities and health systems in high-burden settings.

Learn more: bit.ly/4wSkvCB

08/06/2026

Drugs for Neglected Diseases initiative (DNDi), Global Antibiotic R&D Partnership (GARDP) and MMV are joining forces to accelerate drug development for patients in greatest need. Through a new cooperation agreement, the three organizations will pool expertise and resources, strengthen coordination, and maximize the impact of our global health R&D efforts.

The product development partnership model has demonstrated its ability to deliver life-saving health tools in areas of unmet need. By working even more closely together, we can help accelerate the development of effective and affordable treatments for patients affected by , antimicrobial resistance and neglected diseases.

Read the press release: bit.ly/4fo8xu0

05/06/2026

MMV’s Project of the Year 2025 is a powerful example of how we can go faster and farther by working together.

Coartem® Baby, the first treatment specifically designed for newborns and young infants, is helping close a long-standing treatment gap for the world’s tiniest patients. The medicine recently received WHO prequalification, paving the way for broader access through public health systems.

Developed by Novartis with the scientific and financial support of MMV, and as part of the Africa-Europe PAMAfrica consortium co-funded by EDCTP and Sida, the project reflects years of collaboration spanning research, clinical development and regulation.

This week, we convened the partners behind Coartem® Baby to celebrate its selection as MMV’s Project of the Year award. This award recognizes outstanding drug discovery and development efforts across MMV’s portfolio, as well as the scientific partnerships that help make them possible.

Read more: bit.ly/4en79Xw

03/06/2026

For children with vivax , one infection often leads to repeated illness.

Even after symptoms disappear, the parasite can remain dormant in the liver, causing repeated relapse and disrupting childhood, education and family life.

Thailand is now taking an important step to help break this cycle. The country has become the second in the world, after Brazil, to approve paediatric tafenoquine, a child-friendly single-dose treatment designed to help prevent relapse.

A single-dose treatment helps simplify care, which can make all the difference for children, caregivers and health systems alike.

Thailand’s approval reflects years of implementation research, evidence generation and collaboration, and reinforces the country’s leadership in advancing malaria elimination.

Co-developed by MMV and GSK, paediatric tafenoquine can help children fully recover without the threat of repeated relapse.

Learn more about this milestone: bit.ly/4vehcng

02/06/2026

Calling all African scientists. MMV’s 9th African call for proposals is now open!

Do you have an idea that could help accelerate drug discovery? We’re welcoming submissions in four priority areas:

🔬 Compounds with confirmed activity on any antimalarial lifecycle stage
🧪 Assay development and screening to support the discovery or development of novel antimalarials
👩‍💻 Computer-aided drug discovery
🧬 New innovative biology for malaria prevention and treatment

Spread the word! The deadline to submit applications is 29 August. Learn more: bit.ly/3Rt1h6j

28/05/2026